RxDoctor Payments Data

Samuel Uter, MD

Internal Medicine · Brooklyn, NYNPI 1699713792

Payments from drug & device makers

$135,980in general payments, 2019–2025

Across 425 payments — averaging $319.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$45K
  • Janssen Products, LP$42K
  • Gilead$29K
  • Viiv Healthcare Company$15K
  • Johnson & Johnson$2K
  • Theratechnologies Inc.$2K
  • plus $472 from 13 others

What the payments were for

  • Consulting fees$13,68010%
  • Speaking & faculty fees$99,58573%
  • Travel & lodging$10,2718%
  • Food & beverage$12,2609%
  • Education$1840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,980 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$7,078
Medicare patients
20
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala231$928,799
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf193$897,602
TivicayDolutegravir Sodium95$227,763
DescovyEmtricitabine/Tenofov Alafenam62$188,478
TriumeqAbacavir/Dolutegravir/Lamivudi48$181,323
GenvoyaElviteg/Cob/Emtri/Tenof Alafen39$144,805
DovatoDolutegravir Sodium/Lamivudine47$131,501
JulucaDolutegravir/Rilpivirine37$122,722
JanuviaSitagliptin Phosphate130$113,880
Metformin Er GastricMetformin Hcl11$94,440
PrezcobixDarunavir/Cobicistat24$74,430
StribildElviteg/Cob/Emtri/Tenofo Disop12$46,906
Isentress HdRaltegravir Potassium15$28,155
JardianceEmpagliflozin42$23,811
Etravirine28$22,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya, Stribild, Viread$29,206$1,321,217355 claims
Janssen Products, LPSymtuza$41,793$897,602193 claims
Viiv Healthcare CompanyTivicay, Triumeq, Dovato, Juluca$15,115$663,309227 claims
Johnson & JohnsonPrezcobix, Xarelto$2,324$95,02345 claims
GSKIncruse Ellipta, Trelegy Ellipta, Arnuity Ellipta, Breo Ellipta$50$41,729111 claims
Boehringer IngelheimJardiance$109$23,81142 claims
PfizerEliquis$49$20,53435 claims
Lilly USA, LLCTrulicity$20$17,79420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →